APO RESEARCH · REPORT
Novel Drug Delivery Systems
Novel Drug delivery System (NDDS) refers to the approaches, formulations, technologies, and systems for transporting a pharmaceutical compound in the body as needed to safely achieve its desired therapeutic effects. NDDS is a system for delivery of drug other than conventional drug delivery system. NDDS is a combination of advance technique and new dosage forms which are far better than conventional dosage forms.
Product & engineering
Understand the product.
Novel Drug delivery System (NDDS) refers to the approaches, formulations, technologies, and systems for transporting a pharmaceutical compound in the body as needed to safely achieve its desired therapeutic effects. NDDS is a system for delivery of drug other than conventional drug delivery system. NDDS is a combination of advance technique and new dosage forms which are far better than conventional dosage forms.
Advantages of Novel Drug Delivery System are: Optimum dose at the right time and right location, efficient use of expensive drugs, excipients and reduction in production cost, Beneficial to patients, better therapy, improved comfort and standard of living.
Selected research
Industry Research
Novel Drug Delivery Systems Industry Research Report 2026
Market perspective
Novel Drug delivery System (NDDS) refers to the approaches, formulations, technologies, and systems for transporting a pharmaceutical compound in the body as needed to safely achieve its desired therapeutic effects. NDDS is a system for delivery of drug other than conventional drug delivery system. NDDS is a combination of advance technique and new dosage forms which are far better than conventional dosage forms.
Advantages of Novel Drug Delivery System are: Optimum dose at the right time and right location, efficient use of expensive drugs, excipients and reduction in production cost, Beneficial to patients, better therapy, improved comfort and standard of living.
Global Novel Drug Delivery Systems key players include Amgen, Teva, Roche, UCB (Union Chimique Belge), etc. Global top four manufacturers hold a share over 40%.
Read the full market overview
North America is the largest market, with a share about 50%, followed by Asia-Pacific and Europe, both have a share over 40 percent.
In terms of product, PEGylated Proteins & Polypeptides is the largest segment, with a share about 40%. And in terms of application, the largest application is Hospitals & Clinic, followed by Cancer Treatment Centers, etc.
Report Scope
This report quantifies the global Novel Drug Delivery Systems market in terms of revenue (US$ million) and, where applicable, service volume (K Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Novel Drug Delivery Systems.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Novel Drug Delivery Systems Market by Company
Amgen
Teva
Roche
UCB (Union Chimique Belge)
Celgene
Merck
Gilead Sciences
Sanofi
Pfizer
Takeda
Bausch&Lomb
Samyang Biopharmaceuticals
Johnson & Johnson
TOLMAR
Astellas
AMAG Pharmaceuticals
AbbVie
Dr Reddy
AstraZeneca
Aspen
Acrotech Biopharma
TWi Pharmaceuticals
Novel Drug Delivery Systems Segment by Type
Liposomes
PEGylated Proteins & Polypeptides
Polymer Nanoparticle
Protein–drug Conjugates
Others
Novel Drug Delivery Systems Segment by Application
Hospitals & Clinic
Cancer Treatment Centers
Others
Novel Drug Delivery Systems Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Novel Drug Delivery Systems market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Novel Drug Delivery Systems and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Novel Drug Delivery Systems.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Novel Drug Delivery Systems companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Liposomes
- PEGylated Proteins & Polypeptides
- Polymer Nanoparticle
- Protein–drug Conjugates
- Others
Applications
- Hospitals & Clinic
- Cancer Treatment Centers
- Others
Companies covered
- Amgen
- Teva
- Roche
- UCB (Union Chimique Belge)
- Celgene
- Merck
- Gilead Sciences
- Sanofi
- Pfizer
- Takeda
- Bausch&Lomb
- Samyang Biopharmaceuticals
- Johnson & Johnson
- TOLMAR
- Astellas
- AMAG Pharmaceuticals
- AbbVie
- Dr Reddy
- AstraZeneca
- Aspen
- Acrotech Biopharma
- TWi Pharmaceuticals
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Novel Drug Delivery Systems by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Liposomes
- 2.2.3 PEGylated Proteins & Polypeptides
- 2.2.4 Polymer Nanoparticle
- 2.2.5 Protein–drug Conjugates
- 2.2.6 Others
- 2.3 Novel Drug Delivery Systems by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Hospitals & Clinic
- 2.3.3 Cancer Treatment Centers
- 2.3.4 Others
- 2.4 Assumptions and Limitations
3 Novel Drug Delivery Systems Breakdown Data by Type
- 3.1 Global Novel Drug Delivery Systems Historic Market Size by Type (2021-2026)
- 3.2 Global Novel Drug Delivery Systems Forecasted Market Size by Type (2027-2032)
4 Novel Drug Delivery Systems Breakdown Data by Application
- 4.1 Global Novel Drug Delivery Systems Historic Market Size by Application (2021-2026)
- 4.2 Global Novel Drug Delivery Systems Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Novel Drug Delivery Systems Market Perspective (2021-2032)
- 5.2 Global Novel Drug Delivery Systems Growth Trends by Region
- 5.2.1 Global Novel Drug Delivery Systems Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Novel Drug Delivery Systems Historic Market Size by Region (2021-2026)
- 5.2.3 Novel Drug Delivery Systems Forecasted Market Size by Region (2027-2032)
- 5.3 Novel Drug Delivery Systems Market Dynamics
- 5.3.1 Novel Drug Delivery Systems Industry Trends
- 5.3.2 Novel Drug Delivery Systems Market Drivers
- 5.3.3 Novel Drug Delivery Systems Market Challenges
- 5.3.4 Novel Drug Delivery Systems Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Novel Drug Delivery Systems Players by Revenue
- 6.1.1 Global Top Novel Drug Delivery Systems Players by Revenue (2021-2026)
- 6.1.2 Global Novel Drug Delivery Systems Revenue Market Share by Players (2021-2026)
- 6.2 Global Novel Drug Delivery Systems Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Novel Drug Delivery Systems Head Office and Area Served
- 6.4 Global Novel Drug Delivery Systems Players, Product Type & Application
- 6.5 Global Novel Drug Delivery Systems Manufacturers Established Date
- 6.6 Global Novel Drug Delivery Systems Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Novel Drug Delivery Systems Market Size (2021-2032)
- 7.2 North America Novel Drug Delivery Systems Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Novel Drug Delivery Systems Market Size by Country (2021-2026)
- 7.4 North America Novel Drug Delivery Systems Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Novel Drug Delivery Systems Market Size (2021-2032)
- 8.2 Europe Novel Drug Delivery Systems Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Novel Drug Delivery Systems Market Size by Country (2021-2026)
- 8.4 Europe Novel Drug Delivery Systems Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Novel Drug Delivery Systems Market Size (2021-2032)
- 9.2 Asia-Pacific Novel Drug Delivery Systems Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Novel Drug Delivery Systems Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Novel Drug Delivery Systems Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Novel Drug Delivery Systems Market Size (2021-2032)
- 10.2 South America Novel Drug Delivery Systems Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Novel Drug Delivery Systems Market Size by Country (2021-2026)
- 10.4 South America Novel Drug Delivery Systems Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Novel Drug Delivery Systems Market Size (2021-2032)
- 11.2 Middle East & Africa Novel Drug Delivery Systems Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Novel Drug Delivery Systems Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Novel Drug Delivery Systems Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Amgen
- 12.1.1 Amgen Company Information
- 12.1.2 Amgen Business Overview
- 12.1.3 Amgen Revenue in Novel Drug Delivery Systems Business (2021-2026)
- 12.1.4 Amgen Novel Drug Delivery Systems Product Portfolio
- 12.1.5 Amgen Recent Developments
- 12.2 Teva
- 12.2.1 Teva Company Information
- 12.2.2 Teva Business Overview
- 12.2.3 Teva Revenue in Novel Drug Delivery Systems Business (2021-2026)
- 12.2.4 Teva Novel Drug Delivery Systems Product Portfolio
- 12.2.5 Teva Recent Developments
- 12.3 Roche
- 12.3.1 Roche Company Information
- 12.3.2 Roche Business Overview
- 12.3.3 Roche Revenue in Novel Drug Delivery Systems Business (2021-2026)
- 12.3.4 Roche Novel Drug Delivery Systems Product Portfolio
- 12.3.5 Roche Recent Developments
- 12.4 UCB (Union Chimique Belge)
- 12.4.1 UCB (Union Chimique Belge) Company Information
- 12.4.2 UCB (Union Chimique Belge) Business Overview
- 12.4.3 UCB (Union Chimique Belge) Revenue in Novel Drug Delivery Systems Business (2021-2026)
- 12.4.4 UCB (Union Chimique Belge) Novel Drug Delivery Systems Product Portfolio
- 12.4.5 UCB (Union Chimique Belge) Recent Developments
- 12.5 Celgene
- 12.5.1 Celgene Company Information
- 12.5.2 Celgene Business Overview
- 12.5.3 Celgene Revenue in Novel Drug Delivery Systems Business (2021-2026)
- 12.5.4 Celgene Novel Drug Delivery Systems Product Portfolio
- 12.5.5 Celgene Recent Developments
- 12.6 Merck
- 12.6.1 Merck Company Information
- 12.6.2 Merck Business Overview
- 12.6.3 Merck Revenue in Novel Drug Delivery Systems Business (2021-2026)
- 12.6.4 Merck Novel Drug Delivery Systems Product Portfolio
- 12.6.5 Merck Recent Developments
- 12.7 Gilead Sciences
- 12.7.1 Gilead Sciences Company Information
- 12.7.2 Gilead Sciences Business Overview
- 12.7.3 Gilead Sciences Revenue in Novel Drug Delivery Systems Business (2021-2026)
- 12.7.4 Gilead Sciences Novel Drug Delivery Systems Product Portfolio
- 12.7.5 Gilead Sciences Recent Developments
- 12.8 Sanofi
- 12.8.1 Sanofi Company Information
- 12.8.2 Sanofi Business Overview
- 12.8.3 Sanofi Revenue in Novel Drug Delivery Systems Business (2021-2026)
- 12.8.4 Sanofi Novel Drug Delivery Systems Product Portfolio
- 12.8.5 Sanofi Recent Developments
- 12.9 Pfizer
- 12.9.1 Pfizer Company Information
- 12.9.2 Pfizer Business Overview
- 12.9.3 Pfizer Revenue in Novel Drug Delivery Systems Business (2021-2026)
- 12.9.4 Pfizer Novel Drug Delivery Systems Product Portfolio
- 12.9.5 Pfizer Recent Developments
- 12.10 Takeda
- 12.10.1 Takeda Company Information
- 12.10.2 Takeda Business Overview
- 12.10.3 Takeda Revenue in Novel Drug Delivery Systems Business (2021-2026)
- 12.10.4 Takeda Novel Drug Delivery Systems Product Portfolio
- 12.10.5 Takeda Recent Developments
- 12.11 Bausch&Lomb
- 12.11.1 Bausch&Lomb Company Information
- 12.11.2 Bausch&Lomb Business Overview
- 12.11.3 Bausch&Lomb Revenue in Novel Drug Delivery Systems Business (2021-2026)
- 12.11.4 Bausch&Lomb Novel Drug Delivery Systems Product Portfolio
- 12.11.5 Bausch&Lomb Recent Developments
- 12.12 Samyang Biopharmaceuticals
- 12.12.1 Samyang Biopharmaceuticals Company Information
- 12.12.2 Samyang Biopharmaceuticals Business Overview
- 12.12.3 Samyang Biopharmaceuticals Revenue in Novel Drug Delivery Systems Business (2021-2026)
- 12.12.4 Samyang Biopharmaceuticals Novel Drug Delivery Systems Product Portfolio
- 12.12.5 Samyang Biopharmaceuticals Recent Developments
- 12.13 Johnson & Johnson
- 12.13.1 Johnson & Johnson Company Information
- 12.13.2 Johnson & Johnson Business Overview
- 12.13.3 Johnson & Johnson Revenue in Novel Drug Delivery Systems Business (2021-2026)
- 12.13.4 Johnson & Johnson Novel Drug Delivery Systems Product Portfolio
- 12.13.5 Johnson & Johnson Recent Developments
- 12.14 TOLMAR
- 12.14.1 TOLMAR Company Information
- 12.14.2 TOLMAR Business Overview
- 12.14.3 TOLMAR Revenue in Novel Drug Delivery Systems Business (2021-2026)
- 12.14.4 TOLMAR Novel Drug Delivery Systems Product Portfolio
- 12.14.5 TOLMAR Recent Developments
- 12.15 Astellas
- 12.15.1 Astellas Company Information
- 12.15.2 Astellas Business Overview
- 12.15.3 Astellas Revenue in Novel Drug Delivery Systems Business (2021-2026)
- 12.15.4 Astellas Novel Drug Delivery Systems Product Portfolio
- 12.15.5 Astellas Recent Developments
- 12.16 AMAG Pharmaceuticals
- 12.16.1 AMAG Pharmaceuticals Company Information
- 12.16.2 AMAG Pharmaceuticals Business Overview
- 12.16.3 AMAG Pharmaceuticals Revenue in Novel Drug Delivery Systems Business (2021-2026)
- 12.16.4 AMAG Pharmaceuticals Novel Drug Delivery Systems Product Portfolio
- 12.16.5 AMAG Pharmaceuticals Recent Developments
- 12.17 AbbVie
- 12.17.1 AbbVie Company Information
- 12.17.2 AbbVie Business Overview
- 12.17.3 AbbVie Revenue in Novel Drug Delivery Systems Business (2021-2026)
- 12.17.4 AbbVie Novel Drug Delivery Systems Product Portfolio
- 12.17.5 AbbVie Recent Developments
- 12.18 Dr Reddy
- 12.18.1 Dr Reddy Company Information
- 12.18.2 Dr Reddy Business Overview
- 12.18.3 Dr Reddy Revenue in Novel Drug Delivery Systems Business (2021-2026)
- 12.18.4 Dr Reddy Novel Drug Delivery Systems Product Portfolio
- 12.18.5 Dr Reddy Recent Developments
- 12.19 AstraZeneca
- 12.19.1 AstraZeneca Company Information
- 12.19.2 AstraZeneca Business Overview
- 12.19.3 AstraZeneca Revenue in Novel Drug Delivery Systems Business (2021-2026)
- 12.19.4 AstraZeneca Novel Drug Delivery Systems Product Portfolio
- 12.19.5 AstraZeneca Recent Developments
- 12.20 Aspen
- 12.20.1 Aspen Company Information
- 12.20.2 Aspen Business Overview
- 12.20.3 Aspen Revenue in Novel Drug Delivery Systems Business (2021-2026)
- 12.20.4 Aspen Novel Drug Delivery Systems Product Portfolio
- 12.20.5 Aspen Recent Developments
- 12.21 Acrotech Biopharma
- 12.21.1 Acrotech Biopharma Company Information
- 12.21.2 Acrotech Biopharma Business Overview
- 12.21.3 Acrotech Biopharma Revenue in Novel Drug Delivery Systems Business (2021-2026)
- 12.21.4 Acrotech Biopharma Novel Drug Delivery Systems Product Portfolio
- 12.21.5 Acrotech Biopharma Recent Developments
- 12.22 TWi Pharmaceuticals
- 12.22.1 TWi Pharmaceuticals Company Information
- 12.22.2 TWi Pharmaceuticals Business Overview
- 12.22.3 TWi Pharmaceuticals Revenue in Novel Drug Delivery Systems Business (2021-2026)
- 12.22.4 TWi Pharmaceuticals Novel Drug Delivery Systems Product Portfolio
- 12.22.5 TWi Pharmaceuticals Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst